Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide.
Roche commenced operations in the U.S. over 100 years ago and these
operations include research and development centers that conduct
leading-edge work in advancing disease detection and treatment. Our
diagnostics and pharmaceuticals businesses in the U.S. employ more than
20,000 people and generate approximately $10 billion in sales (including
Genentech), accounting for about 40% of the Roche Group's global annual
For further information, please visit http://www.roche.com.
All trademarks used or mentioned in this release are protected by law.
-- All documents on the offer to Ventana's shareholders:
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org
-- Daniel Piller (Head of Roche Group Media Relations)
-- Alexander Klauser
Brunswick Group (for U.S. media)
Phone: +1 212 333 3810
-- Steve Lipin
-- Nina Devlin
MacKenzie Partners (for U.S. investors)
Phone: +1 212 929 5500
-- Larry Dennedy
-- Bob Marese
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
THIS DOCUMENT CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS. THESE
FORWARD- LOOKING STATEMENTS MAY BE IDENTIFIED BY WORDS SUCH AS 'BELIEVES',
'EXPECTS', 'ANTICIPATES', 'PROJECTS', 'INTENDS', 'SHOULD', 'SEEKS',
'ESTIMATES', 'FUTURE' OR SIMILAR EXPRESSIONS OR BY DISCUSSION OF, AMO
Copyright©2008 PR Newswire.
All rights reserved